Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab added to pemetrexed + carboplatin + bevacizumab after EGFR-TKI failure in EGFR-mutant advanced non-squamous NSCLC
ChiCTR2400094816Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sintilimab, pemetrexed, carboplatin and bevacizumab in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: 12-month progression-free survival rate and disease control rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
sintilimabpemetrexedcarboplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400094816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094816.